Answers are grounded in this paper and cite their sources.
Long-acting antiretroviral chemical compounds and monoclonal antibodies have demonstrated potent anti-HIV activity in the early-stage clinical investigations, and are actively being studied in advanced clinical trials for treatment and prevention. Strategies to manage toxicities and waning drug levels of chemical compounds, as well as primary and secondary resistance to current monoclonal antibodies are important considerations.
No takes yet. Share an insight, caveat, or question.
Jacobson et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: